Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment with SGN-35 (brentuximab vedotin) in CD30-positive hematologic malignancies
2010-019932-11Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jun 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in hematopoietic malignancies and anaplastic large cell lymphoma (ALCL), sponsored by Seagen Inc. Primary endpoints: Safety of retreatment with SGN-35 and Duration of tumor control. Started Jun 2010; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
hematopoietic malignanciesanaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2010-019932-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019932-11.